Should I Get a Hysterectomy If I Have HPV?

Having HPV alone is not a reason to get a hysterectomy. Most HPV infections, even those caused by high-risk strains, clear on their own within a year or two without any surgical intervention. A hysterectomy enters the conversation only when HPV has already driven the development of persistent high-grade precancerous changes or invasive cervical cancer that less aggressive treatments have failed to resolve. The gap between “I tested positive for HPV” and “I need my uterus removed” is enormous, and understanding what fills that gap is the key to making a well-informed decision with your doctor.

Most HPV Infections Resolve Without Treatment

The single most important thing to understand is that your immune system handles most HPV infections on its own. A longitudinal study tracking women in Ethiopia found that roughly three-quarters of those with high-risk HPV had cleared the virus within six months, and close to 87% had cleared it within two years.¹ A large retrospective study from Guangdong, China, found that clearance rates for high-risk HPV specifically ran around 57%.² The numbers vary across populations, but the direction is consistent: most infections go away.

The infections that stick around, the persistent ones, are the ones that matter clinically. Persistent high-risk HPV, especially types 16 and 18, can drive cellular changes in the cervix over months or years. Those changes are graded as cervical intraepithelial neoplasia, or CIN, on a scale from 1 to 3. CIN1 is mild and usually resolves on its own. CIN2 can go either way. CIN3 is a genuine precancer that, left untreated, carries a real risk of progressing to invasive cervical cancer. A positive HPV test without any of these changes calls for monitoring, not surgery.

When Hysterectomy Actually Becomes an Option

Even when you have confirmed high-grade precancerous changes, a hysterectomy is typically not the first treatment offered. The standard approach is an excisional procedure, most commonly a loop electrosurgical excision procedure (LEEP), which removes the affected tissue from the cervix while leaving the uterus intact. This is an outpatient procedure with a short recovery time, and it works well for most women with CIN2 or CIN3.

Hysterectomy enters the picture under specific circumstances: when excisional treatments have failed to clear the precancerous cells, when the abnormal cells keep recurring after one or more excisions, when there are coexisting gynecological conditions like heavy bleeding or fibroids that independently warrant removing the uterus, or when early-stage invasive cancer has been diagnosed. A multi-center retrospective study of women who underwent hysterectomy for cervical dysplasia found that on final pathology, about 72% had CIN of some grade confirmed, and roughly 1.2% had an occult invasive cancer that hadn’t been detected before surgery. But it also found that about 27% of cases showed no pathology or only CIN1, suggesting a meaningful proportion were overtreated.³

That overtreatment figure should give you pause. It means that for roughly one in four women in this study, hysterectomy removed healthy tissue or tissue with changes that likely would have resolved on their own. This is precisely why guidelines emphasize exhausting less invasive options first.

Hysterectomy Does Not Eliminate HPV

A common misconception is that removing the cervix and uterus removes the virus entirely. It does not. HPV infects the epithelial cells of the lower genital tract, and that includes the vaginal walls. After a total hysterectomy, the virus can persist in vaginal tissue and potentially cause vaginal intraepithelial neoplasia (VaIN), a precancerous change in the vaginal lining.

Research makes this risk concrete. One study found that among women with a history of cervical dysplasia who had undergone hysterectomy, the rate of persistent high-risk HPV infection was about 19%. Among those with persistent infection, roughly 36% went on to develop VaIN. Women with HPV16 specifically had a VaIN rate as high as 50%.⁴ A separate study confirmed that all cases of high-grade VaIN occurred in women with persistent HPV infection after their hysterectomy, and that persistent infection raised the odds of developing VaIN substantially.⁵

There is even a documented case of vaginal cuff cancer diagnosed just six months after a complete hysterectomy in a patient whose surgery was for fibroids but who also had low-grade CIN and HPV. Her vaginal HPV DNA levels actually increased after the surgery.⁶ A single case doesn’t define the risk, but it illustrates that hysterectomy is not a cure for HPV itself. If your goal is simply to eliminate the virus from your body, surgery cannot guarantee that.

What Happens With Post-Hysterectomy Follow-Up

An Irish study of women who underwent hysterectomy specifically for cervical dysplasia found that at six months, about a quarter still tested positive for HPV and a fifth had cytological abnormalities on their vault smear. Only 83% even had the recommended follow-up test, falling well below the 95% target set by national guidelines. Postoperative complications affected about 21% of patients.⁷

For women who had their hysterectomy for benign reasons unrelated to HPV or dysplasia, routine vaginal screening is generally not recommended. The risk of vaginal cancer after hysterectomy for benign disease is extremely low. But for women who had their hysterectomy because of precancer or cancer, ongoing surveillance with HPV testing is important for catching vaginal precancers early.⁸ Despite this guidance, a significant number of women who don’t need screening still get it. One institution found that 29% of post-hysterectomy Pap tests performed were not clinically indicated, generating excess costs with a very low diagnostic yield.⁹

Subtotal Hysterectomy Leaves the Cervix Behind

If you’ve had or are considering a subtotal (also called supracervical) hysterectomy, which removes the uterus but leaves the cervix in place, HPV-related screening remains necessary. You still have a cervix, and it can still develop dysplasia or cancer from persistent HPV. A retrospective analysis of women who needed secondary removal of the cervical stump after subtotal hysterectomy found that cervical dysplasia was one of the three main reasons for the second surgery, accounting for about 18% of cases. In some patients, unexpected premalignant or malignant findings led to immediate stump removal.¹⁰ Choosing a subtotal hysterectomy for other reasons doesn’t change your HPV management at all; you still need regular cervical screening just as you would without any surgery.

HPV Genotype Matters More Than You Think

Not all high-risk HPV infections carry the same threat. HPV16 stands out dramatically. One study found that having HPV16 was associated with a roughly 12-fold greater risk of developing a high-grade lesion compared with other types, and that co-infections involving HPV16 together with types 18 or 31 were the most common combinations found in CIN3 lesions.¹¹ This matters for your decision-making because the urgency of treatment escalation depends heavily on which strain you’re dealing with. A persistent HPV16 infection with high-grade changes gets taken more seriously than a persistent HPV52 infection with the same findings, and for good reason.

Some women develop multicentric lesions, meaning HPV drives precancerous changes at multiple sites in the lower genital tract simultaneously, such as the cervix and vagina together, or the cervix and vulva. This occurs in a small minority, roughly 4-5% of women referred for cervical dysplasia in one series, but it’s more common in women with immune disorders.¹² Analysis of these multicentric cases shows that the same HPV type was found across the different sites in nearly half of HPV-positive patients, with HPV16 being the dominant type at vaginal, vulvar, and anal sites.¹³ When multicentric disease is present, a hysterectomy addresses only the cervical component. The other affected sites still need separate management.

Vaccination After Treatment Can Reduce Recurrence

Here is something many women with HPV don’t know: getting the HPV vaccine after an excisional procedure like LEEP may substantially lower the chance of your precancerous cells coming back. A study of over 700 women with CIN2 or CIN3 who underwent LEEP found that only about 2.5% of those who received the quadrivalent HPV vaccine after surgery developed recurrence, compared with about 7.2% of those who did not. Among women specifically infected with HPV16 or 18, the vaccinated group had a recurrence rate of 2.5% versus 8.5% in the unvaccinated group. Not being vaccinated after LEEP was an independent risk factor for recurrence.¹⁴

A more recent prospective study reinforced this finding. Among women who received the vaccine after LEEP, the recurrence rate for high-grade lesions was about 2%, compared with nearly 11% in the unvaccinated group. Regression analysis showed that women without HPV vaccination had dramatically higher odds of recurrence.¹⁵ If your doctor is recommending hysterectomy because of recurrent CIN after LEEP, ask whether post-procedure vaccination was part of your initial treatment plan. If it wasn’t, this may be a less invasive avenue to explore before moving to major surgery.

Timing Matters If Hysterectomy Follows an Excision

When a hysterectomy does become necessary after a prior excisional procedure, timing the two surgeries matters. Performing a minimally invasive hysterectomy too soon after a cervical excision raises the risk of complications. One study found that women who had definitive surgery within six weeks of a cervical excision were about 2.6 times more likely to experience complications within 30 days compared with those who waited longer.¹⁶ A separate study found that a longer interval between LEEP and laparoscopic hysterectomy significantly reduced infectious complications.¹⁷ If you are proceeding with hysterectomy after a recent excision, advocate for waiting at least six weeks unless there’s a compelling reason not to.

Keeping Your Ovaries Is Usually the Right Call

If you do end up needing a hysterectomy for HPV-related disease, one of the most consequential decisions is whether your ovaries stay or go. For younger women especially, ovarian conservation matters enormously. A large study of women under 50 with early-stage cervical cancer found that those who kept their ovaries had significantly better overall survival than those who had them removed, with the benefit driven largely by lower rates of death from cardiovascular disease and other chronic conditions. Cancer-specific survival was similar either way.¹⁸

The concern some surgeons raise is that cancer could recur on a conserved ovary. A propensity-matched study found that this happened in only about 1.3% of cases, while ovarian conservation was independently protective against recurrence overall. Meanwhile, roughly 60% of women in the ovary-removal group reported menopausal symptoms during follow-up, compared with about 21% in the conservation group.¹⁹ The evidence strongly favors keeping your ovaries unless there is a specific oncologic reason to remove them.

Long-Term Pelvic Floor Risks

Hysterectomy, regardless of the reason it’s performed, carries long-term consequences for pelvic floor support. A nationwide cohort study found that total hysterectomy was associated with an increased risk of pelvic organ prolapse.²⁰ A larger population study found that about 3.2% of women who had a hysterectomy eventually needed prolapse surgery, compared with 2% of women who hadn’t had one, with vaginal hysterectomy carrying the highest risk. The effect of prior vaginal deliveries compounded the risk further.²¹

A 10-year follow-up study added nuance, finding that the surgical approach mattered. Laparoscopic-assisted vaginal hysterectomy was associated with a threefold higher risk of subsequent prolapse surgery compared with abdominal hysterectomy, and vaginal vault prolapse specifically was about four times more likely.²² These risks don’t mean you shouldn’t have a hysterectomy when it’s genuinely warranted, but they are part of the tradeoff calculation that gets lost when the surgery is framed as a simple fix. If your precancerous changes can be managed with an outpatient excision, you avoid these downstream risks entirely.

HPV and Immunosuppression

Women living with HIV or other conditions that suppress immune function face a different landscape. Their bodies are less likely to clear HPV spontaneously, and precancerous changes tend to progress faster and recur more readily after treatment. About a fifth of women with multicentric lower genital tract lesions in one series had immunologic disorders.¹² For women with HIV specifically, expert guidance states that radical hysterectomy can be performed for the usual oncologic indications and that surgical decisions should be based on the cancer, not the HIV status. Women with relatively preserved immune function tolerate the surgery well without significant excess complications.²³

That said, the threshold for closer surveillance and earlier intervention is generally lower in immunocompromised women. If you are in this group and dealing with persistent high-risk HPV, your provider may move more quickly through the treatment ladder. But even here, “more quickly” still means trying conservative approaches before jumping to hysterectomy in the absence of invasive cancer.

The Cost and Quality-of-Life Calculation

Hysterectomy is, unsurprisingly, the most expensive strategy for managing cervical precancer. A cost-effectiveness analysis comparing different management strategies for CIN2 and CIN3 found that total vaginal hysterectomy was the most expensive and most effective approach, while simpler office-based treatments were the least expensive and least effective.²⁴ “Most effective” in that analysis meant the lowest recurrence rate, which makes sense: you can’t have cervical recurrence without a cervix. But a more recent study of hysterectomy after conservative treatment for a specific type of precancer (adenocarcinoma in situ) found that the additional surgery gained no quality-adjusted life years and cost over eight times more. Only under the unrealistic assumption that the hysterectomy had zero impact on quality of life did it show any benefit, and even then the cost per quality-adjusted year gained was far above standard thresholds.²⁵

The psychological dimension is real, too. Research has consistently found that a diagnosis of cervical precancer and its treatment are associated with worse psychological outcomes, including anxiety and distress, compared with normal screening results. The impact tends to fade over time, but for some women the emotional burden of repeated abnormal tests and procedures is itself a factor in their decision-making. That is a legitimate consideration to raise with your doctor, alongside the clinical data, when weighing whether a definitive surgery would give you peace of mind or whether the physical tradeoffs outweigh the psychological relief.